Compare AVPT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVPT | SNDX |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | 3443 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2014 |
| Metric | AVPT | SNDX |
|---|---|---|
| Price | $13.43 | $20.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $16.64 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $25.00 | $107.19 |
| Revenue Next Year | $19.63 | $41.88 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $8.84 | $13.00 |
| 52 Week High | $16.77 | $25.59 |
| Indicator | AVPT | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.88 | 54.42 |
| Support Level | $12.92 | $19.20 |
| Resistance Level | $13.71 | $20.88 |
| Average True Range (ATR) | 0.41 | 0.75 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 49.84 | 83.00 |
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.